0001493152-26-016854
SEC filingRevenue increased 16% to $17.4M driven by new sleep testing and treatment services, but operating losses widened 78% to -$19.9M due to elevated SCN operations costs outpacing topline gains amid persistent profitability challenges.
Revenue rose 16.0% to $17.4 million in FY 2025 from $15.0 million in FY 2024, primarily due to an increase in sleep testing services and revenue from Vivos treatments launched at two SCN locations. This growth occurred despite credits offered to VIPs to incentivize product adoption and case volume, and variable consideration from promotions and discounts. The Strategic Alliance Agreement with Rebis Health, entered in June 2024, was anticipated to drive patient volume, top-line revenue, and reduced customer acquisition costs and overhead, though integration dynamics shaped outcomes.
Gross profit improved 16.9% to $10.5 million, maintaining a healthy 60.4% margin versus 60.0% prior year, as higher volumes in diagnostics and treatments balanced elevated costs of sales, including intercompany transactions for SCN treatment centers where payables are settled and expenses recognized.
Net income swung to -$21.2 million from -$11.1 million, a -90.1% change, with diluted EPS narrowing to -$2.07 from -$2.22—a 6.8% improvement attributable to share count effects amid losses. These results highlight ongoing profitability hurdles despite topline momentum.
Liquidity remains a focal point, with financial statements prepared under GAAP assuming going concern continuation. Management notes risks in raising capital, cutting costs, or generating revenue to meet equity requirements, emphasizing the high-stakes pivot to vertical integration via SCN and alliances like Rebis Health.